Allergan Acquires LiRIS® Program from TARIS Biomedical®

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 13, 2014
  • TARIS LiRIS® Program in Phase 2 Clinical Development for the Localized Treatment of Interstitial Cystitis / Bladder Pain Syndrome
  • Acquisition Enhances Allergan’s Leadership Position in Urology and Reinforces the Company’s Commitment to Developing Innovative Treatments to Address Important Medical Needs

Seventh Sense Biosystems Closes $16 Million Series B Financing

Seventh Sense Biosystems Closes $16 Million Series B Financing

August 13, 2014

CAMBRIDGE, Mass., Aug 13, 2014 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc. (7SBio), the pioneering developer of virtually painless blood collection and diagnostic platforms, today announced a $16 million Series B financing from a syndicate of global leaders in diagnostic technologies, pharmaceuticals and clinical diagnostic laboratory services.

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

August 13, 2014

CAMBRIDGE, Mass., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results

August 13, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.

Joule to Present Transformative Climate Change Solution at Arendal Week

Joule to Present Transformative Climate Change Solution at Arendal Week

August 12, 2014

Solar conversion of waste CO2 to fuels can simultaneously cut emissions and enable sustainable transportation

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update

August 12, 2014

LEXINGTON, Mass., Aug 12, 2014 (BUSINESS WIRE) -- Concert Pharmaceuticals, Inc.today reported financial results for the second quarter of 2014.

Acceleron Pharma Reports Second Quarter 2014 Financial Results

Acceleron Pharma Reports Second Quarter 2014 Financial Results

August 12, 2014

--Encouraging interim data presented from five phase 2 clinical trials --

-- Two additional phase 2 studies initiated --

-- Pipeline advancement and expansion demonstrate potential value of late-stage clinical opportunities --

BIND Therapeutics Reports Second Quarter 2014 Financial Results

BIND Therapeutics Reports Second Quarter 2014 Financial Results

August 7, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the second quarter ended June 30, 2014.

Is this the next big leap for organ transplants?

Is this the next big leap for organ transplants?

August 7, 2014

For decades an ordinary picnic cooler has been the the best way to transport donated organs. One entrepreneur thinks we can do much better — and save more lives.

WHEN THE REVELATION CAME, it came in the middle of the night. Waleed Hassanein was a first-year surgical resident at Georgetown University School of Medicine, on the path to becoming a cardiac surgeon. He had worked toward that career for years — in Egypt, in London, and now at a prestigious American hospital. His family, having produced its share of doctors, would proudly add him to the list.

T2 Biosystems Announces Pricing of Initial Public Offering

T2 Biosystems Announces Pricing of Initial Public Offering

August 7, 2014

LEXINGTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. All of the common stock is being offered by T2 Biosystems. In addition, T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock from the company at the public offering price.